Basilea Recovers With Astellas Deal For Phase III Anti-Fungal Following J&J Break-Up
This article was originally published in PharmAsia News
Executive Summary
Switzerland's Basilea licensed its Phase III anti-fungal isavuconazole to Japan's Astellas Pharma Feb. 24, just days after Johnson & Johnson revealed it was pulling out of its five-year deal with the biotech on the delayed antibiotic ceftobiprole